Julie R. Gralow, MD: The Atlas Trial. Tamoxifen For Five Years or Ten Years?
Dr. Julie Gralow sits down with Selma Schimmel and The Group Room at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) for a four-part interview. This is the second in the four-pa...
Author: vitaloptions
Added: 02/26/2013 (Source: Oncology Tube)
Source: Oncology Tube - February 26, 2013 Category: Cancer & Oncology Source Type: podcasts
The Lancet: January 21, 2011
Discussion of the TEAM trial; tamoxifen and exemestane for early breast cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - January 21, 2011 Category: General Medicine Authors: The Lancet Source Type: podcasts
The Lancet: December 18, 2009
Professor Kathy Albain discusses chemotherapy and tamoxifen use for postmenopausal women with node-positive breast cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - December 18, 2009 Category: Journals (General) Authors: The Lancet Source Type: podcasts
JAMA: 2006-06-21, Vol. 295, No. 23, Author in the Room Audio Interview
Interview with Victor G. Vogel, MD, MHS, author of Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes , published in the June 21 issue of JAMA, the Journal of the American Medical Association. Summary Points: 1. Raloxifene is as effective in reducing the risk of invasive breast cancer in postmenopausal women who are at increased risk of the disease. 2. The safety profile of raloxifene is more favorable than tamoxifen with fewer hysterectomies, uterine malignancies, serious thrombotic events, and cataracts. 3. Both physicians and patients are familiar with raloxife...
Source: JAMA Author in the Room - July 19, 2006 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
